Literature DB >> 19688780

Cost-effectiveness acceptability curves--caveats quantified.

Michał Jakubczyk1, Bogumił Kamiński.   

Abstract

Cost-effectiveness acceptability curves (CEACs) have become widely used in applied health technology assessment and at the same time are criticized as unreliable decision-making tool. In this paper we show how using CEACs differs from maximizing expected net benefit (NB) and when it can lead to inconsistent decisions. In the case of comparing two alternatives we show the limits of the discrepancy between CEAC and expected NB approach and link it with expected value of perfect information. We also show how the shape of CEAC is influenced by the skewness of estimate of expected NB distribution, the correlation between cost and effect estimates and their variance. In the case of more than two options we show when using CEACs can lead to non-transitive choices in pair-wise comparisons and when it lacks independence of irrelevant alternatives property in joint comparisons. Copyright (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 19688780     DOI: 10.1002/hec.1534

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  5 in total

1.  Output correlations in probabilistic models with multiple alternatives.

Authors:  Klemen Naveršnik
Journal:  Eur J Health Econ       Date:  2014-01-04

2.  Cost-effectiveness acceptability curves revisited.

Authors:  Maiwenn J Al
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

3.  Impact of small study bias on cost-effectiveness acceptability curves and value of information analyses.

Authors:  Dirk Müller; Eleanor Pullenayegum; Afschin Gandjour
Journal:  Eur J Health Econ       Date:  2014-05-20

4.  Dengue vector control strategies in an urban setting: an economic modelling assessment.

Authors:  Paula Mendes Luz; Tazio Vanni; Jan Medlock; A David Paltiel; Alison P Galvani
Journal:  Lancet       Date:  2011-05-03       Impact factor: 79.321

5.  Comparing multiple competing interventions in the absence of randomized trials using clinical risk-benefit analysis.

Authors:  Alejandro Lazo-Langner; Marc A Rodger; Nicholas J Barrowman; Tim Ramsay; Philip S Wells; Douglas A Coyle
Journal:  BMC Med Res Methodol       Date:  2012-01-10       Impact factor: 4.615

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.